Sotigalimab
- Generic Name
- Sotigalimab
- Drug Type
- Biotech
- CAS Number
- 2305607-45-6
- Unique Ingredient Identifier
- JEA93WJ5DG
- Background
Sotigalimab is under investigation in clinical trial NCT03123783 (CD40 Agonistic Antibody APX005M in Combination With Nivolumab).
Switch Maintenance in Pancreatic
- Conditions
- Pancreatic CancerAdenocarcinoma of the PancreasSquamous Cell Carcinoma of PancreasAdenosquamous Carcinoma of the Pancreas
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- James Cleary, MD, PhD
- Target Recruit Count
- 46
- Registration Number
- NCT05419479
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
APX005M in Patients With Recurrent Ovarian Cancer
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
- Registration Number
- NCT05201001
- Locations
- 🇩🇰
NSGO-CTU, Copenhagen, Sjaelland, Denmark
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
- Conditions
- Advanced MelanomaRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 26
- Registration Number
- NCT04495257
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
- Conditions
- CancerCancer of SkinMelanomaUnresectable MelanomaMetastatic MelanomaMelanoma (Skin)
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Apexigen America, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04337931
- Locations
- 🇵🇱
Centrum Onkologii - Instytutu im. Marii Skłodowskiej - Curie w Warszawie, Warsaw, Poland
🇵🇱Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu, Poznan, Poland
🇪🇸Hospital Universitari Vall D'Hebron, Barcelona, Spain
APX005M and Doxorubicin in Advanced Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Alexander Z. Wei, MD
- Target Recruit Count
- 27
- Registration Number
- NCT03719430
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Columbia University Irving Medical Center/NYP, New York, New York, United States
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
- Conditions
- Non-small Cell Lung CancerAdvanced MelanomaRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 42
- Registration Number
- NCT03502330
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 129
- Registration Number
- NCT03214250
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Stanford University, Stanford, California, United States
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
- Conditions
- Esophageal CancerGastroEsophageal Cancer
- Interventions
- Radiation: Radiation TherapyProcedure: Surgical resection of tumor
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Apexigen America, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03165994
- Locations
- 🇺🇸
Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Renovatio Clinical, The Woodlands, Texas, United States
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
- Conditions
- Metastatic MelanomaNon Small Cell Lung Cancer MetastaticMelanomaCancerNeoplasm of Lung
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Apexigen America, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT03123783
- Locations
- 🇪🇸
H. Doce de Octubre, Madrid, Spain
🇪🇸H. Vall d'Hebron, Barcelona, Spain
🇪🇸H. Lucus Augusti, Lugo, Spain
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT02706353
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.